Illumina, Inc. (ILMN) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $130.32. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ILMN = $143.90 (+10.4% from the current price, the stock appears fairly valued). Analyst consensus target is ILMN = $147 (+12.9% upside).
Valuation: ILMN trades at a trailing Price-to-Earnings (P/E) of 22.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.63.
Financials: revenue is $4.3B, -1.8%/yr average growth. Net income is $850M, growing at +79.3%/yr. Net profit margin is 19.6% (healthy). Gross margin is 66.5% (+1.7 pp trend).
Balance sheet: total debt is $2.6B against $2.7B equity (Debt-to-Equity (D/E) ratio 0.94, moderate). Current ratio is 2.08 (strong liquidity). Debt-to-assets is 38.4%. Total assets: $6.6B.
Analyst outlook: 25 / 50 analysts rate ILMN as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 66/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 83/100 (Pass), Moat 76/100 (Pass), Future 52/100 (Partial), Income 70/100 (Pass).
